Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest and most well-known American pharmaceutical companies.

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, & Head of Development starting Aug 2025.

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers. Did ...